Inhaled hyperosmolar agents for bronchiectasis.

Area of Science:

• Pulmonary Medicine
• Respiratory Physiology

Background:

• Mucus retention is a key feature of bronchiectasis, leading to bacterial colonization and airway damage.
• Neutrophilic response to bacteria fails to clear infections and may worsen lung injury.
• Hypertonic saline and inhaled dry powder mannitol show potential for improving mucus clearance.

Purpose of the Study:

• To evaluate the efficacy of inhaled hyperosmolar substances for treating bronchiectasis.

Main Methods:

• Searched MEDLINE and Cochrane databases, contacting field experts.
• Included trials using hyperosmolar inhalation in non-cystic fibrosis bronchiectasis patients.
• Analyzed data from one identified crossover trial involving 11 patients.

Main Results:

• Inhaled dry powder mannitol doubled tracheobronchial clearance in central and intermediate lung regions.
• No adverse effects were reported, though two patients received premedication for bronchospasm.
• Peripheral airway clearance did not show significant improvement.

Conclusions:

• Dry powder mannitol enhances tracheobronchial clearance in bronchiectasis, similar to its effects in other respiratory conditions.
• Hypertonic saline has demonstrated benefits in chronic bronchitis and other conditions, but requires specific testing in bronchiectasis.
• Long-term, randomized controlled studies are necessary to confirm the clinical efficacy of mannitol and hypertonic saline in bronchiectasis.